Idylla™, Biocartis' fully automated, real-time PCR-based molecular diagnostics system

Konference: 2015 11. sympózium molekulovej patológie s medzinárodnou účasťou a Martinské dni nelekárskych pracovníkov v patológii

Kategorie: Onkologická diagnostika

Téma: MODERNÁ PATOLÓGIA PRE KLINICKÚ PRAX

Číslo abstraktu: 010

Autoři: David Favy, Ph.D.

Idylla™, Biocartis' fully automated, real-time PCR-based molecular diagnostics system is designed to offer fast access to clinical molecular diagnostic information, anywhere and anytime. The Idylla™ system works on-demand in virtually any laboratory setting, allowing even decentralized laboratories to rapidly report results. Idylla™ covers the entire process from sample to result in a time frame of 40 to 150 minutes.

This allows laboratories to report same-day results, so physicians have the information needed to make timely decisions. The fully integrated system enables clinical laboratories to perform a broad range of applications, including oncology, infectious diseases and genetic testing.

About 50 percent of all melanomas harbor mutations in the BRAF oncogene. Idylla™, Biocartis' fully automated, real-time PCR, offers fast and easy access to high-quality biomarker data. Idylla™ BRAF Mutation Test allows detection of BRAF mutations directly from FFPE (1) tissue sections in 90 minutes with less than 2 minutes hands-on time. A game-changing technology when time matters most.

About 50 % of all metastatic colorectal tumors harbor mutations in exons 2, 3 and 4 of the KRAS oncogene1. Idylla™, Biocartis' fully automated, real-time PCR, offers fast and easy access to high quality biomarker data. The Idylla™ KRAS Mutation Assay allows detection of KRAS mutations directly from formalin-fixed paraffin-embedded (FFPE) tissue sections in approx. 2 hours with less than 2 minutes hands-on time. The Idylla™ KRAS Mutation Assay is capable of detecting 21 relevant KRAS mutations: 7 muta­tions in codons 12 and 13 (exon 2), 9 mutations in codons 59 and 61 (exon 3) and 5 mutations in codons 117 and 146 (exon 4); at an average sensitivity of 1 % based on research data. The game-changing real-time PCR based technology uses a unique combination of ARC primers and MNAzymes, which allows very high sensitivity and specificity combined with high multiplexing capability.

Datum přednesení příspěvku: 4. 6. 2016